CD8A and melanoma: Analysis of transcriptomes of melanoma patients before and during nivolumab treatment revealed that clinical benefit was associated with reduced expression of SLC3A2, enhanced CD8+ T cell signature and expression of IFNG that was associated with improved overall patient survival [198].